Rights and Permissions
Mark H Wilcox, Galia Rahav, Erik R Dubberke, Lori Gabryelski, Kerrie Davies, Claire Berry, Karen Eves, Misoo C Ellison, Dalya Guris, Mary Beth Dorr, Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II, Open Forum Infectious Diseases, Volume 6, Issue 8, August 2019, ofz293, https://doi.org/10.1093/ofid/ofz293 © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact email@example.com DOI: 10.1093/ofid/ofz293 https://academic.oup.com/ofid/article/6/8/ofz293/5543265
Wilcox, Mark H.; Rahav, Galia; Dubberke, Erik R.; Gabryelski, Lori; Davies, Kerrie; Berry, Claire; Eves, Karen; Ellison, Misoo C.; Guris, Dalya; and Dorr, Mary Beth, ,"Influence of diagnostic method on outcomes in phase 3 clinical trials of bezlotoxumab for the prevention of recurrent Clostridioides difficile infection: A post hoc analysis of MODIFY I/II." Open Forum Infectious Diseases.,. . (2019).